LON:RENE - ReNeuron Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 75.50 0.00 (0.00 %)
(As of 03/22/2019 04:00 PM ET)
Previous CloseGBX 75.50
Today's RangeGBX 74 - GBX 75.60
52-Week RangeGBX 1.37 - GBX 142.50
Volume30,510 shs
Average Volume28,700 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. It is also involved in developing human retinal progenitor cell candidate, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, a blindness-causing disease of the retina, as well as that is in Phase I clinical trial to treat cone-rod dystrophy, an inherited eye disorder; and CTX-derived exosomes, which are nanoparticles released by cells containing various active proteins and microRNAs. ReNeuron Group plc was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-38198400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees62
Next Earnings DateN/A
OptionableNot Optionable

ReNeuron Group (LON:RENE) Frequently Asked Questions

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How were ReNeuron Group's earnings last quarter?

ReNeuron Group Plc (LON:RENE) posted its quarterly earnings data on Friday, December, 14th. The company reported ($16.80) earnings per share (EPS) for the quarter. View ReNeuron Group's Earnings History.

Has ReNeuron Group been receiving favorable news coverage?

Media headlines about RENE stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ReNeuron Group earned a news sentiment score of 2.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of ReNeuron Group's key competitors?

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include International Road Dynamics (IRD), Sareum (SAR), AXA (CS), Lloyds Banking Group (LLOY), Regenxbio (RGNX), Connect Group (CNCT), Sirius Minerals (SXX), ValiRx (VAL), Independent Oil & Gas (IOG) and Spark Therapeutics (ONCE).

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the folowing people:
  • Mr. Olav Hellebø, CEO & Director (Age 54)
  • Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)
  • Dr. Randolph Corteling, Head of Research
  • Mr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs

How do I buy shares of ReNeuron Group?

Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 75.50.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is http://www.reneuron.com/.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.


MarketBeat Community Rating for ReNeuron Group (LON RENE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  97 (Vote Underperform)
Total Votes:  256
MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe RENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Featured Article: Conference Calls

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel